T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7T

Investigative Radiology

Volumn 50, Issue 5, 2015, Pages 330-338

  Shen, Yaqi ^a   Goerner, Frank L ^b,c,d   Snyder, Christopher ^b   Morelli, John N ^e   Hao, Dapeng ^f   Hu, Daoyu ^a   Li, Xiaoming ^a   Runge, Val M ^g  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f QINGDAO UNIVERSITY   (China)

^g University Hospital Zurich Institut fur Diagnostische Radiologie   (Switzerland)

Author keywords

1.5 T; 3 T; 7 T; comparative studies; field strength dependence; gadolinium; MRI contrast media; relaxivity; whole blood

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM BASED MAGNETIC RESONANCE CONTRAST AGENT; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

ARTICLE; AUTOMATION; BLOOD; CONTROLLED STUDY; DILUTION; DOSE CALCULATION; DOSIMETRY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING PHANTOM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RELAXATION TIME; SIGNAL PROCESSING; BLOOD ANALYSIS; CHEMISTRY; COMPARATIVE STUDY; IMPEDANCE; MATERIALS TESTING; PROCEDURES;

BLOOD CHEMICAL ANALYSIS; CONTRAST MEDIA; ELECTRIC IMPEDANCE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MATERIALS TESTING;

EID: 84928631936     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000132     Document Type: Article

References (21)

1. Hao D, Ai T, Goerner F, et al. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging. 2012;36:1060-1071
2. Runge VM, Ai T, Hao D, et al. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011; 46:807-816
3. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla [published erratum appears in Invest Radiol 2006;41:859]. Invest Radiol. 2006;41:213-221
4. Stanisz GJ, Henkelman RM. Gd-DTPA relaxivity depends on macromolecular content. Magn Reson Med. 2000;44:665-667
5. Goetschi S, Froehlich JM, Chuck NC, et al. The protein and contrast agent-specific influence of pathological plasma-protein concentration levels on contrast-enhanced magnetic resonance imaging. Invest Radiol. 2014;49:608-619
6. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228
7. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol. 1999;9:998-1004
8. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724
9. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137
10. Blockley NP, Jiang L, Gardener AG, et al. Field strength dependence of R1 and R2∗ relaxivities of human whole blood to ProHance, Vasovist, and deoxyhemoglobin. Magn Reson Med. 2008;60:1313-1320
11. Ogg RJ, Kingsley PB. Optimized precision of inversion-recovery T1 measurements for constrained scan time. Magn Reson Med. 2004;51:625-630
12. Kingsley PB, MonahanWG. Effect of increased repetition time TR on precision of inversion-recovery T(1) measurements. Magn Reson Imaging. 2001;19:279-282
13. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538
14. Noebauer-Huhmann IM, Szomolanyi P, Juras V, et al. Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest Radiol. 2010;45:554-558
15. Rane SD, Gore JC.Measurement of T1 of human arterial and venous blood at 7T. Magn Reson Imaging. 2013;31:477-479
16. Lin AL, Qin Q, Zhao X, et al. Blood longitudinal (T1) and transverse (T2) relaxation time constants at 11.7 Tesla. MAGMA. 2012;25:245-249
17. Dobre MC, Ugurbil K, Marjanska M. Determination of blood longitudinal relaxation time (T1) at high magnetic field strengths. Magn Reson Imaging. 2007;25: 733-735
18. Lu H, Clingman C, Golay X, et al. Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. Magn Reson Med. 2004;52:679-682
19. Shimada K, Nagasaka T, Shidahara M, et al. In vivo measurement of longitudinal relaxation time of human blood by inversion-recovery fast gradient-echo MR imaging at 3T. Magn Reson Med Sci. 2012;11:265-271
20. Wang Y, Spiller M, Caravan P. Evidence for weak protein binding of commercial extracellular gadolinium contrast agents. Magn Reson Med. 2010;63:609-616
21. Henrotte V, Vander EL, Laurent S, et al. Comprehensive investigation of the noncovalent binding ofMRI contrast agents with human serum albumin. J Biol Inorg Chem. 2007;12:929-937